URALENSIS INNOV8 LTDActive

Company number 10653081Private limited companyIncorporated 2017

Key figures

£60,345+9.0%
Net assets 2024/25
+58.9%
Average annual growth 2020/21–2024/25
020 k40 k60 k80 k2020/212021/222022/232023/242024/25

Like most small UK companies, URALENSIS INNOV8 LTD does not publish a profit and loss account in its latest accounts. The figures below come from the balance sheet.

Ratios

2024/25
Balance sheet structure
Current assetsFixed assetsLiabilitiesNet assets
0500 k1 m2020/212021/222022/232023/242024/25
Filed accounts2020/21–2024/25
2020/212021/222022/232023/242024/25
Cash at bank and in hand———329,159188,912
Total assets166,054769,730190,397585,082571,289
Total liabilities156,592739,559151,027——
Net assets / total equity9,46230,17130,11255,38060,345
Average number of employees778810

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Summary: URALENSIS INNOV8 LTD

Company

URALENSIS INNOV8 LTD is a private limited company registered with Companies House under company number 10653081. It was incorporated on 6 Mar 2017. Its status is active. The registered office is in Carlisle (CA3). Its nature of business (SIC 2007) is business and domestic software development (62012), post-graduate level higher education (85422), specialists medical practice activities (86220), other human health activities (86900).

Accounts

The latest accounts in the database are for 2024/25 (period ending 31 Mar 2025); the company files small company accounts (filleted). Net assets were £60,345, up 9% on the previous year. Cash at bank and in hand was £188,912. The company had an average of 10 employees. Figures are available for 5 financial years (2020/21–2024/25).

Control and charges

2 persons with significant control are registered.

Filing deadlines

The next accounts are due by 31 Dec 2026. The next confirmation statement is due by 7 Aug 2027.